Received Mar 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
patient who received first dose of GARDASIL 9 at 11 years of age came to their facility at 20 years of age to complete the series; No additional AE details provided; This spontaneous report was received from Other health professional and refers to a 20-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date (reported as at 11 years of age), the patient was vaccinated with 1 dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (strength, frequency, route of administration, site of administration, vaccination scheme, expiration date, and lot # were not reported). On unknown date (reported as at 20 years of age), the patient went to the facility to complete the series with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), (strength, frequency, route of administration, site of administration, vaccination scheme, expiration date, and lot # were not reported) as a prophylaxis (Inappropriate schedule of product administration). No additional AE details provided was unknown.